Day TWO of #PROSCA25
#GlobalForum25 in Portugal π΅πΉ
Presentation by Eva CompΓ©rat during the Looking ahead: PCa management in 2026
Discussing the View of the Pathologist
Genetic testing has become a routine part of clinical practice, w/ biomarkers playing an increasingly important role
Day TWO of #PROSCA25
#GlobalForum25 in Portugal π΅πΉ
Presentation by Rob Jones π¬π§ during the Looking ahead: PCa management in 2026 Session
Discussing The View of the Oncologist
Day TWO of #PROSCA25
#GlobalForum25 in Portugal π΅πΉ
Thomas Zilli π¨π Presenting in the Looking ahead: PCa management in 2026 Session
Discussing View of the radiation oncologistβ’οΈ
The future of radiotherapy for #ProstateCancer is moving beyond a βone-size-fits-allβ approach toward more personalized
Day TWO of #PROSCA25
#GlobalForum25 in Portugal π΅πΉ
LΓ©a Turpin π«π· Presents Update lecture: The future of radioligands in PCa
PSMA PET/CT is rapidly becoming the new gold standard for imaging prostate cancer, offering superior detection and staging capabilities
Day TWO of #PROSCA25
#GlobalForum25 in Portugal π΅πΉ
Presenting Update lecture: Will AI replace the physician in PCa treatment?
Presentation by Badrinath Konety πΊπΈ
#ProstateCancer
Day TWO of #PROSCA25
#GlobalForum25 in Portugal π΅πΉ
Presentation by Aurelius Omlin π¨πduring the Case discussion session: CRPC
Presenting: Targeting CRPC with PARPi & immunotherapy
#ProstateCancer
Arthur, a 71-year-old patient experiencing symptomatic progression on ADT plus enzalutamide
Day TWO of #PROSCA25
#GlobalForum25 in Portugal π΅πΉ
Presentation by Bertrand Tombal π§πͺ during the Case discussion session: CRPC
Presenting: Combination approaches in first-line CRPC #ProstateCancer
Multiple major guidelines strongly endorse the use of bone-protecting agents (BPAs) i
Day ONE of #PROSCA25
#GlobalForum25 in Portugal π΅πΉ
Presentation by Bertrand Tombal π§πͺ during the Case discussion session: mHSPC Session
Discussing Treatment de-escalation in mHSPC
In metastatic hormone-sensitive #ProstateCancer , many patients achieve a deep PSA response w/ ADT + ARPI
Day ONE of #PROSCA25
#GlobalForum25 in Portugal π΅πΉ
Presentation by VΓ©rane Achard π«π· during the Unfavourable intermediate- and high-risk PCa Session
Presenting : Optimising treatment in high-risk BCR patients
#ProstateCancer
Day ONE of #PROSCA25
#GlobalForum25 in Portugal π΅πΉ
Presentation by Julien Van Damme π§πͺ during the Unfavourable intermediate- and high-risk PCa Session
Presenting: PSA-only monitoring in BCR
PSA-only biochemical recurrence represents a highly heterogeneous disease state
#ProstateCancer
Day ONE of #PROSCA25
#GlobalForum25 in Portugal π΅πΉ
Presentation by Bertrand Tombal π§πͺ during the Unfavourable intermediate- and high-risk PCa Session
Presenting: Treatment strategies for elderly with locally advanced #ProstateCancer
It has been an incredible few days at #RENALC25 and #BLADDR25, with a combined 4.3 million impressionsβand the numbers continue to rise. Today, we launch the oldest and largest meeting of the series: #GLOBALFORUM25 / #PROSCA25!
Day TWO of #BLADDR25
#GlobalForum25 in Portugal π΅πΉ
Presentation from Ben-Max de Ruiter π³π± during The Non Muscle Invasive #BladderCancer Case Discussion Session: Challenges and innovations in tumour resection and ablation
Day TWO of #BLADDR25
#GlobalForum25 in Portugal π΅πΉ
Presentation from Ananya Choudhury π¬π§ during The Clinical Questions Session discussing How to treat Histological Subtypes of the Bladder. #BladderCancer
Day TWO of #BLADDR25
#GlobalForum25 in Portugal π΅πΉ presentation from Dr. Pieter De Visschere π§πͺ
#BladderCancer
Session: Back to the Future 10 Years of BLADDR
From Past to future: View of the Radiologist
From AI to PET CT, the future is Bright
Day TWO of #BLADDR25
#GlobalForum25 in Portugal π΅πΉ Kicking off with a presentation from Dr. Bente Thoft Jensen π©π°
Session: What really matters to patients for whom cystectomy is planner
The role of pre- and rehabilitation
Day One of #BLADDR25 #GlobalForum25 in Portugal π΅πΉ
Presenting Dr. Ananya Choudhury from the UK π¬π§
Session: Case discussion session: MIBC
Debate: Management of a 4 cm cT3N0M0 tumour
Day One of #BLADDR25 #GlobalForum25 in Portugal π΅πΉ
Presenting Dr. Geert Smits from the Netherlandsπ³π±
Debate: Management of a 4 cm cT3N0M0 tumour
Partial Cystectomy/Brachytherapy
Day One of #BLADDR25 #GlobalForum25 in Portugal π΅πΉ
Presenting Dr. Ben-Max De Ruiter from the Netherlands π³π±
Case discussion session: MIBC
New concepts in bladder preservation
#BladderCancer
Day One of #BLADDR25 #GlobalForum25 in Portugal π΅πΉ
Kicking off with a presentation from Dr. Eva Comperat of Vienna, Austriaπ¦πΉ & Paris, Franceπ«π·
Session: Moving down in the urinary system: UTUC
Presenting: Genomic/tumour characterisation
Day One of #RENALC25 #GlobalForum25 in Portugal π΅πΉ
Great presentation during the Case discussion session: From locally advanced to metastatic RCC session from Dr. Lisa Pickering from London, UKπ¬π§
Progression after IO: Whatβs next?
Day One of #RENALC25 #GlobalForum25 in Portugal π΅πΉ
Great presentation from Dr. Axel Bex from London, UKπ¬π§
Emerging neoadjuvant treatment approaches in #KidneyCancer Discussion on the PROSPER Trial and discussion on where to go moving forward
Day One of #RENALC25 #GlobalForum25 in Portugal π΅πΉ
Great Debate presentation from Dr. Axel Bex from London, UKπ¬π§
Advancements in imaging and local disease management : Debate on Management of T1 Tumors. Cryoablation , Opera Trial & NEST cohort embedded randomized feasibility Trial #KidneyCancer
Kicking off Day One of #RENALC25 #GlobalForum25 in Portugal π΅πΉ
Kicking off with a presentation from Dr. Pieter De Visschere from Ghent, Belgium π§πͺ
Imaging innovations in Renal Cell Carcinoma #KidneyCancer
Discussing Traditional diagnostic workup of renal mass & MRI Clear Cell Likelihood score
In about 30 minutes we KICK off the #GlobalForum25 with #RENALC25 , #BLADDR25 and ending with #PROSCA25 discussing the latest in #KidneyCancer #BladderCancer and #ProstateCancer with an amazing internationa faculty!